PenTAG Health Technology Assessment

PenTAG is the team of researchers within ESMI that specialise in conducting health technology assessment for national policy makers in England and Wales.

PenTAG is one of several university-based research groups in the UK contracted to produce high quality systematic reviews and economic analyses of health technologies for NICE, the UK National Screening Committee and the NIHR HTA programme.

Our work supporting NICE falls under three categories:

  • Multiple Technology Appraisals (MTAs) – We produce systematic reviews of the existing literature on clinical and cost-effectiveness, critique analyses from manufacturers and develop a new economic analysis to support decisions when multiple technologies are being appraised. These projects lead to published monographs in the journal Health Technology Assessment and can also lead to journal articles. Past MTA projects
  • Single Technology Appraisals (STAs) – We perform a rapid review of the evidence supporting a new drug or medical device supplied to NICE by the manufacturer. This helps to ensure that all relevant clinical effectiveness evidence is included, that cost-effectiveness analyses are robust, and that Appraisal Committees are confident that methods have been independently reviewed. Past STA projects
  • Diagnostics Assessment (DA) – A relatively new process, similar to that for MTAs, for which we undertake an assessment of the diagnostic test accuracy, clinical outcomes and cost-effectiveness of a diagnostic technology. These projects lead to published monographs in the journal Health Technology Assessment and can also lead to journal articles.

In addition staff members actively seek additional research funding in areas of interest to them, often stemming from work commissioned by NICE or NIHR.

Our research staff come from a variety of backgrounds, including specialists in systematic review methods, health economics, information science, computer science and statistics. We are additionally able to draw on substantial expertise from other groups in the Institute for Health Research, such as the health statistics and health economics groups.

Release of our economic models
We are happy to consider releasing copies of our economic models of health technologies to not-for-profit organisations within the UK or overseas, such as other universities or government agencies. Please contact Martin Hoyle.

Workstream Lead: Prof Martin Hoyle

Current projects

FunderProjectTeam
NIHR DAR Lung cancer screening by low dose CT T Snowsill, H Yang, E Griffin, L Long, J Varley-Campbell, H Coehlo, S Robinson, C Hyde
NICE DAR PartoSure (and alternative technologies identified during scoping) to help predict preterm labour in women with intact membranes J Varley-Campbell, R Mujica-Mota, H Coehlo, C Cooper, I Tikhonova, H Yang, M Hoyle, C Hyde
NICE MTA Everolimus, lanreotide, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression M Haasova, J Varley-Campbell, I Tikhonova, M Hoyle, R Mujica-Mota, E Griffin, S Lucherini, C Cooper

Past projects
NICE MTAs, DARs and NIHR HTAs

FunderProjectAuthorsPublications
NICE DAR Genetic testing for Lynch syndrome in people with colorectal cancer H Coehlo, T Jones-Hughes, C Hyde, T Snowsill, N Huxley, C Cooper, S Briscoe  
NIHR HTA Effectiveness and cost-effectiveness of conservative interventions for tendinopathy: an overview of systematic reviews of clinical effectiveness and systematic review of economic evaluations L Long, S Briscoe, C Cooper, C Hyde, L Crathorne Monograph
NICE MTA Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer N Huxley, L Crathorne, J Varley-Campbell, I Tikhonova, T Snowsill, S Briscoe, J Peters, M Napier, M Bond, M Hoyle  
NIHR HTA Cost-effectiveness of screening for permanent hearing loss in children at school entry

H Fortnum, C Benton, C Hyde, J Moody, R Taylor, O Ukoumunne, A Allardice, M Ozolins, S Catterick, E Youngman, N Huxley, T Snowsill  
NIHR CLAHRC South West Peninsula (PenCLAHRC) and NIHR Psychological consequences of false-positive screening mammograms M Bond, C Hyde  
NICE MTA Erythropoiesis stimulating agents (epoetin and darbepoetin) for cancer-treatment induced anaemia L Crathorne, N Huxley, M Haasova, T Snowsill, T Jones‑Hughes, M Hoyle, S Briscoe, H Coelho, L Long, A Medina‑Lara, R Mujica‑Mota, C Hyde  
NICE MTA Immunosuppressive therapy for renal transplantation in adolescents and children (including a review of existing guidance 99) R Anderson, M Bond, C Cooper, L Crathorne, M Haasova, R Mujica‑Mota, T Snowsill, N Huxley Monograph
NICE MTA Immunosuppressive therapy for renal transplantation in adults (including a review of existing guidance 85) R Anderson, M Bond, H Coelho, C Cooper, M Haasova, T Jones‑Hughes, J Varley-Campbell, R Mujica‑Mota, T Snowsill, M Allwood, N Huxley Monograph
NICE DA Sysmex RD-100i OSNA system and Metasin for intraoperative detection of sentinel lymph node metastases in breast cancer (monograph in press) N Huxley, T Jones‑Hughes, H Coelho, T Snowsill, C Cooper, K Cooper, Y Meng, C Hyde, R Mujica‑Mota  Monograph
NIHR HTA Diagnostic strategies for identifying Lynch syndrome in early-onset colorectal cancer patients (monograph in press) T Snowsill, N Huxley, M Hoyle, T Jones‑Hughes, H Coelho, C Cooper, I Frayling, C Hyde

MonographJournal article (BMC Cancer)

NICE MTA Bevacizumab, Cetuximab, and Panitumumab for in colorectal cancer (metastatic) after failure of 1st line chemotherapy M Hoyle, L Crathorne, J Peters, T Jones‑Hughes, C Cooper, M Napier, P Tappenden, C Hyde

Monograph
Journal article (Value in Health)

NIHR HTA Psychological consequences of false positive mammograms M Bond, T Pavey, K Welch, C Cooper, R Garside, S Dean, C Hyde Monograph
Journal article (Editor's choice, Evidence Based Medicine)
NICE MTA Dasatinib and Nilotinib for the 1st line treatment of chronic phase CML T Pavey, M Hoyle, O Ciani, L Crathorne, T Jones‑Hughes, C Cooper, L Osipenko, M Venkatachalam, C Rudin, O Ukoumunne, R Garside, R Anderson Monograph
NICE MTA Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant or imatinib-intolerant CML G Rogers, M Hoyle, J Thompson Coon, T Moxham, Z Liu, M Pitt, K Stein Monograph
Journal article (Value in Health)
NICE MTA Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease M Bond, G Rogers, J Peters, R Anderson, M Hoyle, A Miners, T Moxham, S Davis, P Thokala, A Wailoo, M Jeffreys, C Hyde Monograph
Journal article #1 (International Journal of Technology Assessment in Health Care)
Journal article #2 (Age and Ageing)
NIHR HTA Computerised decision support systems in Order Communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems C Main, T Moxham, JC Wyatt, J Kay, R Anderson, K Stein Monograph
NICE MTA Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: A systematic review and economic model J Thompson Coon, M Hoyle, C Green, Z Liu, K Welch, T Moxham, K Stein Monograph
Journal article #1 (Value in Health)
Journal article #2 (Value in Health)
Journal article #3 (British Journal of Cancer)
NIHR HTA Weight management schemes for the under fives M Bond, K Wyatt, J Lloyd, K Welch, R Taylor Monograph
NICE MTA Cochlear implants for severe to profound deafness in children and adults M Bond, S Mealing, R Anderson, J Elston, G Weiner, R Taylor, M Hoyle, Z Liu, A Price, K Stein Monograph
Journal article #1 (Clinical Otolaryngology)
Journal article #2 (updated searches; Clinical Otolaryngology)
NICE MTA Methods of storing donated kidneys from deceased donors  M Bond, M Pitt, J Akoh, T Moxham, M Hoyle, R Anderson Monograph
NIHR HTA Systematic review of the harmful health effects of taking ecstasy (MDMA) for recreational purposes G Rogers, J Elston, R Garside, C Roome, R Taylor, P Younger, A Zawada, M Somerville Monograph
NIHR HTA

Surgical procedures and non-surgical devices for the management of non-apnoeic snoring: a systematic review of clinical effects and associated treatment costs

C Main, Z Liu, K Welch, G Weiner, SQ Jones, K Stein

Monograph

 

Some further past projects can be found here.

 

NICE STAs

IDTitleAuthorsReport
  Regorafenib for treating advanced gastrointestinal stromal tumours T Jones-Hughes, J Dunham, S Robinson, M Napier, M Hoyle  
  Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma I Tikhonova, T Jones-Hughes, J Dunham, F Warren, S Robinson, P Stephens, M Hoyle

Journal article
(PharmacoEconomics)

TA399 Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts R Mujica Mota, J Varley-Campbell, I Tikhonova, C Cooper, M Hoyle, C Rudin, T Snowsill Journal article (PharmacoEconomics)
  Lenalidomide for multiple myeloma post bortezomib (Celgene) N Huxley, L Long, M Hoyle, C Rudin, S Briscoe  
ID642 Ofatumumab in combination with chlorambucil or bendamustine for previously untreated chronic lymphocytic leukaemia: a critique of the submission from GSK.  STA for NICE M Hoyle, N Huxley, H Coelho, J Lowe, C Cooper, L Crathorne, J Peters, C Rudin Report
ID650 Obinutuzumab in combination with chlorambucil for previously untreated chronic lymphocytic leukaemia: a critique of the submission from Roche. STA for NICE M Hoyle, L Long, N Huxley, L Crathorne, S Briscoe, C Rudin Report
TA299 Bosutinib for previously-treated chronic myeloid leukaemia (CML) M Hoyle, T Snowsill, M Haasova, C Cooper, C Rudin  Evaluation report (item 13; errata item 15)
TA219 Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer M Pitt, L Crathorne, T Moxham, M Bond, C Hyde Monograph supplement
TA216 Bendamustine for the treatment of chronic lymphocytic leukaemia L Crathorne, M Hoyle, T Jones‑Hughes, K Stein ERG report
TA202 Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab M Hoyle, L Crathorne, R Garside, C Hyde Monograph supplement
TA179 Sunitinib for the treatment of gastrointestinal stromal tumours M Bond, M Hoyle, T Moxham, M Napier, R Anderson Monograph supplement
TA174 The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche C Main, M Pitt, T Moxham, K Stein Monograph supplement
TA171 Lenalidomide for multiple myeloma in people who have received at least one prior therapy R Garside, M Hoyle, T Moxham, G Rogers, K Stein ERG report
TA127 Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis R Garside, C Green, M Hoyle, R Taylor, A Price, K Stein ERG report

Staff